Clinical updates on carvedilol: A first choice β-blocker in the treatment of cardiovascular diseases

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 2, 2010, Pages 237-250

  Chakraborty, Subhashis ^a   Shukla, Dali ^a   Mishra, Brahmeshwar ^a   Singh, Sanjay ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

blocker; Cardiovascular disease; Carvedilol; Carvedilol phosphate; Chronic heart failure; Hypertension; Left ventricular dysfunction

Indexed keywords

ACEBUTOLOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; BISOPROLOL FUMARATE; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESMOLOL; FLUOXETINE; HYDROCHLOROTHIAZIDE; LABETALOL; METOPROLOL; METOPROLOL TARTRATE; NADOLOL; PENBUTOLOL; PINDOLOL; PROPAFENONE; PROPRANOLOL; QUINIDINE; SOTALOL; TIMOLOL MALEATE;

ACUTE HEART INFARCTION; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BRADYCARDIA; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CENTRAL SLEEP APNEA SYNDROME; CHEST TIGHTNESS; CLINICAL TRIAL; COLD LIMB; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS SURGERY; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG EFFECT; DRUG ELIMINATION; DRUG ERUPTION; DRUG FORMULATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DYSPNEA; EDEMA; ELECTROPHYSIOLOGY; ENDOTHELIAL DYSFUNCTION; FACE EDEMA; FATIGUE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE DYSFUNCTION; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEMODYNAMICS; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; LIP EDEMA; MAXIMUM PLASMA CONCENTRATION; MORBIDITY; MORTALITY; MOUTH EDEMA; NAUSEA; PARESTHESIA; PATHOPHYSIOLOGY; PRURITUS; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TONGUE EDEMA; URTICARIA; VOMITING; WEAKNESS; WEIGHT GAIN;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; CARDIOVASCULAR DISEASES; HUMANS; PROPANOLAMINES;

EID: 76749102823     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903540220     Document Type: Review

References (97)

1. Mathers C, Lopez A, Murray CJ. Global burden of disease and risk factors. Oxford University Press, New York; 2006
2. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-1757
3. Leeder S, Raymond S, Greenberg H, et al. A race against time: the challenge of cardiovascular disease in developing countries. Trustees of Columbia University, New York; 2004
4. Steg PG, Bhatt DL, Wilson PW, et al. One year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-1206
5. Tardif JC. Heart rate as a treatable cardiovascular risk factor. Br Med Bull 2009;90:71-84
6. Fonarow GC. Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol. Expert Opin Pharmacother 2006;18:2533-2546
7. Skolnik NS, Beck JD, Clark M. Combination antihypertensive drugs: recommendations for use. Am Fam Physician 2000;61:3049-3056
8. Boer RA, Veldhuisen DJ. ACE-inhibitors, beta-blockers or the combination in heart failure: is it just an A-B-C? Cardiovasc Drugs Ther 2008;22:261-263
9. Kaplan N. Systemic hypertension: therapy. In: Zipes D, Libby P, Bonow R, et al. editors, Braunwald's heart disease. A textbook of cardiovascular medicine. 7th edition. Elsevier Saunders, Philadelphia, Pensylvania; 2005
10. Opie L, Yusuf S. Beta-blocking agents. In: Opie LH, Gersh B editors, Drugs for the heart. 6th edition. WB Saunders Company, Philadelphia, Pensylvania; 2005
11. Frishman WH. Carvedilol. N Engl J Med 1998;339:1759-1765
12. Sica DA. Beta-blockers in hypertension: a reassessment of the benefit of combined alpha-/beta-blockade. J Clin Hypertens 2007;9:4-9
13. Broeders MA, Doevendans PA, Bekkers BC, et al. Nebivolol: a third generation beta-blocker that augments vascular nitric oxide release; endothelial beta (2)-adrenergic receptor- mediated nitric oxide production. Circulation 2000;102:677-684
14. Rxlist. The Internet Drug Index. Available from: http://www.rxlist.com/ script/main/ hp.asp. [Last accessed 7 September 2009]
15. Ruffolo RR, Gellai M, Hieble JR, et al. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990;38:S82-8
16. Luo CH, Rudy Y. A model of the ventricular cardiac action potential. Depolarization, repolarization, and their interaction. Circ Res 1991;68:1501-1526
17. Davidenko JM, Antzelevitch C. Electrophysiological mechanisms underlying rate-dependent changes of refractoriness in normal and segmentally depressed canine Purkinje fibers. The characteristics of post-repolarization refractoriness. Circ Res 1986;58:257-268
18. Kanoupakis EM, Manios EG, Mavrakis HE, et al. Electrophysiological effects of carvedilol administration in patients with dilated cardiomyopathy. Cardiovasc Drugs Ther 2008;22:169-176
19. Nessler J, Nessler B, Kitliński M, et al. Sudden cardiac death risk factors in patients with heart failure treated with carvedilol. Kardiol Pol 2007;65:1417-1422
20. Hamaad A, Lip GY, Nicholls D, MacFadyen RJ. Comparative dose titration responses to the introduction of bisoprolol or carvedilol in stable chronic systolic heart failure. Cardiovasc Drugs Ther 2007;21:437-444
21. Sevimli S, Yilmaz M, Gundogdu F, et al. Carvedilol therapy is associated with an improvement in left atrial appendage function in patients with congestive heart failure. Echocardiography 2007;24:623-628 (Pubitemid 46956608)
22. Nakamura K, Kusano K, Nakamura Y, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002;105:2867-2871
23. Sawyer DB, Siwik DA, Xiao L, et al. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002;34:379-388
24. Grieve DJ, Shah AM. Oxidative stress in heart failure. More than just damage. Eur Heart J 2003;24:2161-2163
25. Remondino A, Kwon SH, Communal C, et al. Beta adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2- terminal kinase-dependent activation of the mitochondrial pathway. Circ Res 2003;92:136-138
26. Kawai K, Qin F, Shite J, et al. Importance ofantioxidant and antiapoptotic effects of beta-receptor blockers in heart failure therapy. Am J Physiol Heart Circ Physiol 2004;287:H1003-12
27. Feuerstein GZ, Shusterman NH, Ruffolo RR Jr. Carvedilol update IV: prevention of oxidative stress, cardiac remodeling and progression of congestive heart failure. Drugs Today 1997;33:453-473
28. Santos DJ, Moreno AJ. Inhibition of heart mitochondrial lipid peroxidation by non-toxic concentrations of carvediolol and its analog BM-910228. Biochem Pharmacol 2001;61:155-164
29. Banach, M, Okonski P, Kosmider A, et al. Aortic valve replacement in patients with heart failure. Pol Merkur Lekarski 2006;20:642-645
30. Feuerstein GZ, Ruffolo RR. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J 1996;17:24-29
31. Kowalski J, Baszczyk J, Petecka E, et al. Neutrophils superoxide anion generation during carvedilol therapy in patients with stable angina. Int J Cardiol 2005;102:397-402
32. Tadolini B, Franconi F. Carvedilol inhibition of lipid peroxidation. A new antioxidative mechanism. Free Radic Res 1998;5:377-387
33. Bajcetic M, Kokic Nikolic A, Djukic M, et al. Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study. Clin Ther 2008;30:702-714
34. Kastratović DA, Vasiljević ZM, Spasić MB, et al. Carvedilol increases copper-zinc superoxide dismutase activity in patients with acute myocardial infarction. Basic Clin Pharmacol Toxicol 2007;101:138-142
35. Kowalski J, Banach M, Barylski M, et al. Carvedilol modifies antioxidant status of patients with stable angina. Cell Mol Biol Lett 2008;13:230-239
36. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-2825
37. Di Lenarda A, Sabbadini G, Salvatore L, et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 1999;33:1926-1934
38. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999;99:2645-2651
39. Metra M, Giubbini R, Nodari S, et al. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000;102:546-551
40. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 2003;362:7-13
41. Kataoka M, Satoh T, Yoshikawa T, et al. Comparison of the effects of carvedilol and metoprolol on exercise ventilatory efficiency in patients with congestive heart failure. Circ J 2008;72:358-363
42. Haghjoo M, Saravi M, Hashemi MJ, et al. Optimal beta-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol. Heart Rhythm 2007;4:1170-1174
43. Mrdovic IB, Savic LZ, Perunicic JP, et al. Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 2007;154:116-122
44. Acikel S, Bozbas H, Gultekin B, et al. Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery. Int J Cardiol 2009; 135:393-396
45. Widmann L, van der Does R, Hörrmann M, Machwirth M. Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide. Eur J Clin Pharmacol 1990;38:S143-6 (Pubitemid 20184002)
46. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997;126:955-959
47. Merritt JC, Niebauer M, Tarakji K, et al. Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am J Cardiol 2003;92:735-736
48. Tomlinson B, Cronin CJ, Graham BR, Prichard BN. Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol and labetalol. J Cardiovasc Pharmacol 1987;10:S69-75
49. Lin HC, Yang YY, Hou MC, et al. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. Am J Gastroenterol 2004;99:1953-1958
50. Herman RB, Jesudason PJ, Mustafa AM, et al. Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans. Br J Clin Pharmacol 2003;55:134-138
51. Powers DR, Wallin JD. End-stage renal disease in specific ethnic and racial groups: risk factors and benefits of antihypertensive therapy. Arch Int Med 1998;158:793-800
52. Ferdinand KC. Treating the African American with hypertension: does race really matter? South Med J 2000;93(5):541-544
53. Jawa A, Nachimuthu S, Pendergrass M, et al. Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. J Diabetes Complications 2008;22:303-308
54. Flack JM, Hamaty M. Difficult-to-treat hypertensive populations: focus on African-Americans and people with type 2 diabetes. J Hypertens Suppl 1999;17(1):S19-24
55. Doehner W, Rauchhaus M, Ponikowski P, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005;46:1019-1026
56. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996;77:1017-1020
57. Kovacic D, Marinsek M, Gobec L, et al. Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin Res Cardiol 2008;97:24-31
58. Phillips RA, Fonseca V, Katholi RE, et al. Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. J Cardiometab Syndr 2008;3:211-217
59. Javaheri S, Parker TJ, Liming JD, et al. Sleep apnea in 81 ambulatory male patients with stable heart failure: types and their prevalences, consequences, and presentations. Circulation 1998;97:2154-2159 (Pubitemid 28262123)
60. Sin DD, Fitzgerald F, Parker JD, et al. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med 1999;160:1101-1106
61. Tamura A, Kawano Y, Kadota J. Carvedilol reduces the severity of central sleep apnea in chronic heart failure. Circ J 2009;73:295-298
62. Agostoni P, Contini M, Magini A, et al. Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia. Eur J Heart Fail 2006;8:729-735
63. Agostoni P, Contini M, Cattadori G, et al. Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? Eur J Heart Fail 2007;9:827-833
64. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 1994;26:335-346
65. Ruffolo RR Jr, Boyle DA, Venuti RP, Lukas MA. Preclinical and clinical pharmacology of carvedilol. J Hum Hypertens 1993;7:S2-15
66. Tenero D, Boike S, Boyle D, et al. Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. J Clin Pharmacol 2000;40:844-853
67. Neugebauer G, Akpan W, von Möllendorff E, et al. Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol 1987;10:S85-8
68. Frishman WH. Carvedilol. N Engl J Med 1998;339:1759-1765
69. Neugebauer G, Gabor M, Reiff K. Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective fi rst-pass extraction. J Cardiovasc Pharmacol 1992;19:S142-6
70. Gehr TW, Tenero DM, Boyle DA, et al. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 1999;55:269-277
71. Remme WJ, Cleland JG, Erhardt L, et al. Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. Eur J Heart Fail 2007;9:1128-1135
72. Kountz DS. Are tolerability concerns a class effect of beta-blockers in treating patients with hypertension? Postgrad Med 2009;121:14-24
73. Rhodes J, Margossian R, Darras BT, et al. Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol 2008;29:343-351
74. Lainscak M, Moullet C, Schön N, Tendera M. Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience. Int J Cardiol 2007;122:149-155
75. Laer S, Mir TS, Behn F, et al. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 2002;143:916-922
76. Albers S, Meibohm B, Mir TS, Läer S. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. Br J Clin Pharmacol 2008;65:511-522
77. Del Sindaco D, Pulignano G, Cioffi G, et al. Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure. J Cardiovasc Med 2007;8:675-682
78. Weir MR. Beta-blockers in the treatment of hypertension: are there clinically relevant differences? Postgrad Med 2009;121:90-98
79. Che Q, Schreiber MJ Jr, Rafey MA. Beta-blockers for hypertension: Are they going out of style? Cleve Clin J Med 2009;76:533-542
80. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572
81. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997
82. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-569
83. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-640 (Pubitemid 38340037)
84. Dahlöf B, Devereux RB, Kjeldsen SE, et al.; for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003 (Pubitemid 34286536)
85. Dahlöf B, Sever PS, Poulter NR, et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
86. Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst 2006;7:61-63
87. Mancia G, De Backer G, Dominiczak A, et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187
88. Drugs.com. Drug information Online. Available from: http://www.drugs.com/ sfx/carvedilol-side-effects.html. [Last assessed 6 September 2009]
89. Skolnik NS, Beck JD, Clark M. Combination antihypertensive drugs: recommendations for use. Am Fam Physician 2000;61:3049-3056
90. Brook CS, Chen W, Spoors PG. Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/ or methods of treatment. US7268156; 2007
91. Chakraborty S, Shukla D, Jain A, et al. Assessment of solubilization characteristics of different surfactants for carvedilol phosphate as a function of pH. J Colloid Interf Sci 2009;335:242-249
92. Nemergut G. Review of carvedilol in extended-release formulation. J Pharm Soc Wis 2007;9:46-49
93. Henderson LS, Tenero DM, Baidoo CA, et al. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am J Cardiol 2006;98:17L-26L
94. Packer M, Lukas MA, Tenero DM, et al. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Am J Cardiol 2006;98:39L-45L
95. Lemmer B. The importance of circadian rhythms on drug response in hypertension and coronary heart disease-from mice and man. Pharmacol Ther 2006;111:629-651
96. Tenero DM, Henderson LS, Baidoo CA. Pharmacokinetic Properties of a New Controlled-Release Formulation of Carvedilol. Am J Cardiol 2006;98(Suppl):5L-16L
97. Chakraborty S, Shukla D, Mishra B, Singh S. Lipid-An emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm 2009;73:1-15